Clinical Trials Browser

Phase 2 × Salivary Gland Neoplasms × 30 days × Clear all

NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Phase 2 Active not recruiting

45 enrolled 12 charts

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT01220583 2026-05-27

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Phase 2 Active not recruiting

Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT02568267 2026-05-27

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Phase 2 Active not recruiting

Salivary Gland Neoplasms

NCT04325828 2026-05-08

YATAGARASU

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

NCT05074940 2026-05-08

Amivantamab in Adenoid Cystic Carcinoma

Phase 2 Active not recruiting

21 enrolled 13 charts

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms